Laniquidar - CISMeF

Preferred Label : Laniquidar;

NCIt related terms : R101933;

NCIt definition : A stereoisomer of verapamil and third-generation P-glycoprotein inhibitor. Laniquidar inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein. (NCI04);

Alternative definition : NCI-GLOSS: A substance that is being studied for its ability to make cancer cells respond to drugs to which they have become resistant. It belongs to the family of drugs called multidrug resistance inhibitors.;

UNII : K3FRN4DDOY;

InChIKey : TULGGJGJQXESOO-UHFFFAOYSA-N;

CAS number : 197509-46-9;

Molecule name : R101933;

Chemical formula : C37H36N4O3;

Codes from synonyms : CDR0000045068;

Détails

Origin ID

C28698;

UMLS CUI

C0916124;

Automatic exact mappings (from CISMeF team)
- laniquidar [MeSH concept]
- laniquidar [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- laniquidar [MeSH Supplementary Concept]
- laniquidar [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
is_component_of_chemotherapy_regimen
- Docetaxel/Laniquidar [NCIt concept]
- Paclitaxel/R101933 [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients